JPMorgan Chase & Co. set a GBX 1,340 ($17.92) price target on GlaxoSmithKline (LON:GSK) in a research report report published on Thursday morning. The brokerage currently has a neutral rating on the stock.
Several other equities research analysts also recently weighed in on GSK. Investec downgraded GlaxoSmithKline to a hold rating and decreased their target price for the stock from GBX 1,800 ($24.07) to GBX 1,390 ($18.59) in a research report on Monday, November 6th. Shore Capital reaffirmed a hold rating on shares of GlaxoSmithKline in a research report on Wednesday, September 20th. reaffirmed a buy rating and issued a GBX 1,970 ($26.34) target price on shares of GlaxoSmithKline in a research report on Wednesday, September 13th. Jefferies Group reduced their price target on GlaxoSmithKline from GBX 1,750 ($23.40) to GBX 1,675 ($22.40) and set a buy rating for the company in a report on Monday, September 18th. Finally, Liberum Capital reduced their price target on GlaxoSmithKline from GBX 1,900 ($25.40) to GBX 1,760 ($23.53) and set a buy rating for the company in a report on Wednesday, October 4th. Three equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have given a buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus price target of GBX 1,563.33 ($20.90).
Shares of GlaxoSmithKline (GSK) traded up GBX 21.40 ($0.29) during midday trading on Thursday, hitting GBX 1,361 ($18.20). The stock had a trading volume of 9,290,878 shares, compared to its average volume of 8,460,000. GlaxoSmithKline has a 52 week low of GBX 1,270 ($16.98) and a 52 week high of GBX 1,724.50 ($23.06). The stock has a market capitalization of $67,480.00 and a P/E ratio of 2,835.42.
GlaxoSmithKline (LON:GSK) last issued its earnings results on Wednesday, October 25th. The company reported GBX 32.50 ($0.43) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of GBX 31.80 ($0.43) by GBX 0.70 ($0.01). GlaxoSmithKline had a return on equity of 461.88% and a net margin of 17.79%. The company had revenue of GBX 784.30 billion during the quarter.
The business also recently declared a dividend, which will be paid on Thursday, January 11th. Stockholders of record on Thursday, November 9th will be given a dividend of GBX 19 ($0.25) per share. This represents a dividend yield of 1.41%. The ex-dividend date is Thursday, November 9th.
In other news, insider Patrick Vallance sold 20,000 shares of the stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of GBX 1,310 ($17.52), for a total transaction of £262,000 ($350,314.21). Also, insider Simon Dingemans purchased 1,076 shares of the company’s stock in a transaction dated Thursday, October 12th. The shares were bought at an average price of GBX 1,527 ($20.42) per share, for a total transaction of £16,430.52 ($21,968.87). Insiders have bought a total of 1,577 shares of company stock worth $2,400,086 over the last quarter.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.